Trial Profile
A randomized phase II trial of two dose levels of ZD1839 (Iressa) (NSC 715055, IND 61187) in patients with recurrent colorectal adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 20 Dec 2005 Status changed from in progress to completed
- 10 Sep 2005 New trial record.